HLS Therapeutics Inc. (TSE:HLS – Get Free Report) shares fell 0.2% during trading on Monday . The stock traded as low as C$4.35 and last traded at C$4.49. 5,715 shares were traded during trading, a decline of 46% from the average session volume of 10,544 shares. The stock had previously closed at C$4.50.
HLS Therapeutics Stock Performance
The firm has a market cap of C$140.42 million, a price-to-earnings ratio of -9.98 and a beta of 0.54. The firm’s 50 day moving average is C$4.63 and its 200-day moving average is C$5.07. The company has a debt-to-equity ratio of 87.61, a quick ratio of 1.01 and a current ratio of 1.17.
About HLS Therapeutics
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue.
Recommended Stories
- Five stocks we like better than HLS Therapeutics
- 1,500 Banks Just Handed the Fed Your Bank Account
- America’s 1776 happening again
- I’m 70 With $1.5M: Would Converting $120K a Year to a Roth Be Smart or a Costly Mistake? (Ask An Advisor)
- Gilder: Don’t Buy AI Stocks, Do This Instead
- Your name isn’t on our protected list yet
Receive News & Ratings for HLS Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HLS Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
